

# 1 **SARS-CoV-2 disinfection in aqueous solution** 2 **by UV<sub>222</sub> from a krypton chlorine excilamp** 3 4

## 5 **AUTHORS**

6 Richard T. Robinson<sup>1,2</sup>, Najmus Mahfooz<sup>1</sup>, Oscar Rosas-Mejia<sup>1</sup>, Yijing Liu<sup>3</sup>, Natalie M.  
7 Hull<sup>3,4\*</sup>  
8

## 9 **AFFILIATIONS**

- 10 1. Department of Microbial Infection and Immunity, The Ohio State University,  
11 Columbus, OH, USA  
12 2. Infectious Diseases Institute, The Ohio State University, Columbus, OH, USA  
13 3. Department of Civil, Environmental, and Geodetic Engineering, The Ohio State  
14 University, Columbus, OH, USA  
15 4. Sustainability Institute, The Ohio State University, Columbus, OH, USA  
16 \* Corresponding author: Natalie Hull, [hull.305@osu.edu](mailto:hull.305@osu.edu), 2070 Neil Ave, Hitchcock  
17 417C, Columbus, OH,43210  
18

## 19 **KEYWORDS**


20 COVID-19, SARS-CoV-2, UV Disinfection, ultraviolet light, water treatment, coronavirus,  
21 qPCR, plaque assay, infectivity, nucleic acid damage, protein damage, ELISA, RNA  
22  
23

## 24 **ABSTRACT**

25 There is an urgent need for evidence-based development and implementation of  
26 engineering controls to reduce transmission of SARS-CoV-2, the etiological agent of  
27 COVID-19. Ultraviolet (UV) light can inactivate coronaviruses, but the practicality of UV  
28 light as an engineering control in public spaces is limited by the hazardous nature of  
29 conventional UV lamps, which are Mercury (Hg)-based and emit a peak wavelength  
30 (254 nm) that penetrates human skin and is carcinogenic. Recent advances in the  
31 development and production of Krypton Chlorine (KrCl) excimer lamps hold promise in  
32 this regard, as these emit a shorter peak wavelength (222 nm) and are recently being  
33 produced to filter out emission above 240 nm. However, the disinfection kinetics of KrCl  
34 UV excimer lamps against SARS-CoV-2 are unknown. Here we provide the first dose  
35 response report for SARS-CoV-2 exposed to a commercial filtered KrCl excimer light  
36 source emitting primarily 222 nm UV light (UV<sub>222</sub>), using multiple assays of SARS-CoV-  
37 2 viability. Plaque infectivity assays demonstrate the pseudo-first order rate constant of  
38 SARS-CoV-2 reduction of infectivity to host cells to be 0.64 cm<sup>2</sup>/mJ (R<sup>2</sup> = 0.95), which  
39 equates to a D<sub>90</sub> (dose for 1 log<sub>10</sub> or 90% inactivation) of 1.6 mJ/cm<sup>2</sup>. Through RT-  
40 qPCR assays targeting the nucleocapsid (N) gene with a short (<100 bp) and long  
41 (~1000 bp) amplicon in samples immediately after UV<sub>222</sub> exposure, the reduction of  
42 ability to amplify indicated an approximately 10% contribution of N gene damage to  
43 disinfection kinetics. Through ELISA assay targeting the N protein in samples  
44 immediately after UV<sub>222</sub> exposure, we found no dose response of the ability to damage  
45 the N protein. In both qPCR assays and the ELISA assay of viral outgrowth  
46 supernatants collected 3 days after incubation of untreated and UV<sub>222</sub> treated SARS-  
47 CoV-2, molecular damage rate constants were similar, but lower than disinfection rate  
48 constants. These data provide quantitative evidence for UV<sub>222</sub> doses required to  
49 disinfect SARS-CoV-2 in aqueous solution that can be used to develop further  
50 understanding of disinfection in air, and to inform decisions about implementing UV<sub>222</sub>  
51 for preventing transmission of COVID19.

52

53 **ABSTRACT ART / TOC GRAPHIC**



54

55

56

## 57 INTRODUCTION

58 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent  
59 of Coronavirus Disease 2019 (COVID-19), a recently emerged infectious disease with  
60 no cure. SARS-CoV-2 spreads primarily from person to person when mucous  
61 membranes (e.g., lungs, eyes) are exposed to airborne viruses that have been emitted  
62 by infected individuals in particles of various size<sup>1,2</sup>. Infection leads to a variable  
63 disease course affecting multiple organ systems (respiratory, cardiac, neurological and  
64 gastrointestinal); for this reason, the symptoms of COVID19 are variable and include  
65 asymptomatic infection, fever, cough, dyspnea, malaise, nausea, ageusia/anosmia,  
66 delirium and death. A number of antiviral and host-directed therapies have been or are  
67 being explored as COVID19 treatments, including low-dose radiation<sup>3</sup>, nucleoside  
68 analogs (e.g. remdesivir<sup>4</sup>, favipiravir<sup>5</sup>), hydroxychloroquine<sup>6</sup>, interferon beta<sup>7</sup>,  
69 convalescent plasma<sup>8,9</sup>, neutralizing monoclonal antibodies<sup>10,11</sup>, and anti-inflammatories  
70 such as dexamethasone<sup>12</sup>, IL6 inhibitors<sup>13</sup>, and JAK/STAT inhibitors<sup>14</sup>. Prophylactic  
71 vaccines against the SARS-CoV-2 Spike protein have also recently become available<sup>15</sup>.  
72 These treatments and vaccines are causes for optimism during the current COVID19  
73 pandemic, which to date has killed nearly 2 million individuals; however, even after  
74 vaccines become widely available, social distancing, face masks and other engineering  
75 solutions that limit transmission will continue to be needed in the foreseeable future for  
76 this and other emerging infectious diseases<sup>16</sup>.

77  
78 Ultraviolet (UV) irradiation is an effective means of inactivating a number of respiratory  
79 viruses, including human coronavirus OC43 (HCoV-OC43, a cause of the common  
80 cold<sup>17</sup>) and SARS-CoV (etiological agent of the 2002 SARS epidemic<sup>18-20</sup>). UV is  
81 commonly applied for upper room air disinfection, in HVAC systems, and in free-  
82 standing air and surface purifiers. The feasibility of using UV on a widespread and  
83 evidence-based level to minimize transmission of SARS-CoV-2, however, is currently  
84 limited by two reasons: (1) conventional mercury-based low pressure UV lamps are  
85 impractical in many settings as they are hazardous to human health (the 254 nm  
86 wavelength emission causes skin cancer<sup>21</sup> and cataracts<sup>22</sup>) and the environment

87 (mercury from breaking fragile quartz lamp bulbs is toxic<sup>23</sup>), (2) the UV dose response  
88 kinetics needed to inactivate SARS-CoV-2 are unknown. Should these two challenges  
89 be overcome, the use of UV to inactivate SARS-CoV-2 in environments with high  
90 potential for transmission (e.g. congregate care facilities, convalescent patient homes,  
91 hospital waiting rooms, airplane cabins) would be a practical and readily deployed  
92 engineering solution to augment current prophylactic measures (social distancing, face  
93 masks, vaccines). Due to a surge in interest and application of UV in various public  
94 settings, there is an urgent need to understand the dose response kinetics of SARS-  
95 CoV-2 to UV radiation to inform decisions which balance the risk to eyes and skin from  
96 UV exposure with the risk of infection from virus transmission.

97  
98 Here we demonstrate the dose response kinetics of SARS-CoV-2 in liquid after  
99 exposure to primarily 222 nm UV light emitted by a krypton-chlorine (KrCl) excimer lamp  
100 (excilamp) filtered to reduce transmission of more harmful wavelengths > 240 nm. The  
101 lower wavelength emission (222 nm) is neither carcinogenic in human skin models or  
102 rodents<sup>24</sup>, nor causes acute corneal damage in rodents<sup>25</sup>. Additionally, the 222 nm  
103 wavelength emitted by KrCl excilamps is inherently more effective at disinfection<sup>26</sup>,  
104 nucleic acid damage<sup>27</sup>, and protein damage<sup>28,29</sup> than 254 nm emitted by low pressure  
105 mercury lamps due to greater absorbance of target biomolecules at lower wavelengths.  
106 Krypton and chlorine in KrCl excilamps are much less toxic than mercury, and KrCl  
107 excilamps have already been shown to be competitive in terms of electrical efficiency  
108 with mercury lamps that have many more years of product development and  
109 optimization<sup>30</sup>. Our results demonstrate that when an aqueous solution of pathogenic  
110 SARS-CoV-2 is exposed to UV<sub>222</sub> light emitted by a Kr-Cl excilamp, its infectivity and  
111 integrity is attenuated in a UV dose-dependent manner, as measured by culture and  
112 molecular assays. These first UV<sub>222</sub> disinfection dose responses demonstrate the  
113 feasibility of UV as an approach to inactivate SARS-CoV-2.

## 114 **METHODS**


### 115 **SARS-CoV-2 culture**

116 SARS-CoV-2, Isolate USA-WA1/2020, was obtained from Biodefense and Emerging  
117 Infections Research Resources Repository (BEI Resources, Batch # 70034262) and  
118 stored and cultured in the Ohio State University Biosafety Level 3 laboratory (IBC  
119 Protocol # 2020R00000046). The viral stock used in this study was established by  
120 thawing the Batch, diluting it 1:10,000 into incomplete DMEM (Gibco Cat# 11995-065,  
121 supplemented with 4.5 g/L D-glucose, 110 mg/L sodium pyruvate), and adding it to  
122 T175 flasks of confluent Vero cells (ATCC clone E6) for a one hour incubation period  
123 (37°C, 5% CO<sub>2</sub>), after which the supernatant was removed and replaced with complete  
124 DMEM (cDMEM; DMEM as above plus 4% heat-inactivated fetal bovine serum). These  
125 T175 flasks were incubated for 3 days (37°C, 5% CO<sub>2</sub>) to propagate infectious virus. At  
126 the end of this period, visual inspection of the flasks under a light microscope  
127 demonstrated that the nearly all Vero cells were dead. The supernatants in each of the  
128 T175 flasks were presumed to contain infectious virus at this point, were carefully  
129 transferred and combined into a 50mL conical, centrifuged at low speed to remove cell  
130 debris, aliquoted into microcentrifuge tubes, frozen and stored at -80°C. The live virus  
131 titer in frozen aliquots was determined to be ~10<sup>7</sup> plaque forming unit (PFU) per mL  
132 using a modified version of plaque assay developed by the Diamond laboratory<sup>31</sup> and  
133 described below.

### 134 **UV Dose Calculations**

135 The UV<sub>222</sub> light source (USHIO Care222<sup>®</sup>) is a KrCl excilamp that is optically filtered to  
136 reduce emission > 240 nm. The UV source was turned on to warm up for 15 minutes  
137 before any irradiance or spectral measurements or irradiations. Standardized  
138 procedures were followed for carrying out quasi-collimated beam disinfection studies<sup>32</sup>  
139 and calculating polychromatic UV doses<sup>33</sup>. The emission spectrum of the UV<sub>222</sub> source  
140 was measured using a NIST-traceable calibrated Ocean Optics HDX UV-Vis  
141 spectroradiometer with an extreme solarization resistant 455 μ fiber and Spectralon

142 diffusing cosine corrector detector. Raw spectral data from the OceanView software  
143 was interpolated to integer wavelengths using the FORECAST function in Microsoft  
144 Excel and relativized to peak emission at 222 nm for use in dose calculations (Figures 1  
145 and S1). Total incident UV-C irradiance was measured using an International Light  
146 Technologies (ILT) 2400 radiometer with a SED 220/U solar blind detector, W Quartz  
147 wide eye diffuser for cosine correction, and peak irradiance response NIST-traceable  
148 calibration. For irradiance measurement, the peak wavelength calibration value was  
149 input manually as the radiometer factor. The incident irradiance was measured with the  
150 detection plane of the radiometer centered at the height and location of the sample  
151 surface during UV exposures, and corrected for several factors to determine the  
152 average irradiance through the sample depth. Spatial nonuniformity of emission was  
153 accounted for each test by measuring irradiance at 0.5 cm increments from the center  
154 to the edge of the petri dish and relativized to determine a petri factor, which was  
155 always > 0.9. The typical detector spectral response was obtained from ILT and used to  
156 calculate the radiometer factor integrated over the lamp emission, which was 0.9971.  
157 As previously<sup>34</sup>, the reflection factor for water at the 222 nm peak wavelength was  
158 assumed to be 0.9726. The divergence factor was determined each experiment day by  
159 accounting for the distance between the lamp and the sample surface, and the sample  
160 depth and was always > 0.9. The water factor was determined each sample day by the  
161 ratio between the incident irradiance and the average irradiance integrated through the  
162 sample depth after wavelength-specific absorption. The UV-vis absorbance of virus  
163 working stocks (prepared fresh for each test) was measured in the biosafety cabinet  
164 using a Nanodrop<sup>TM</sup> One<sup>C</sup> spectrophotometer via the microvolume pedestal for  
165 wavelengths 200 - 295 nm and the 1 cm quartz cuvette for wavelengths above 195 nm.  
166 Working stock absorbance spectra for each test are shown in Figures 1 and S1. After  
167 these adjustments to incident irradiance in the center of the sample, the average  
168 irradiance was used to calculate exposure times (max: 15 minutes; min: 15 seconds) for  
169 pre-determined UV doses (0-40 mJ/cm<sup>2</sup>) (summarized in Supplementary Table S1).



170

171  
172 **Figure 1:** (A) The raw spectral emission from 200 - 300 nm of the filtered KrCl excilamp  
173 (USHIO Care222<sup>®</sup>) was interpolated and relativized to the peak emission at 222 nm for  
174 use in UV dose calculations. (B) The absorbance spectrum from 200 - 300 nm of SARS-  
175 CoV-2 at  $\sim 10^5$  PFU/mL in cDMEM was measured for each of three biologically  
176 independent Tests for use in UV dose calculations. Expanded emission and  
177 absorbance spectra from 200 - 800 nm are shown in Supplementary Figure S1.

## 178 UV Treatment

179 All UV measurements, sample preparation, UV treatments, and subsequent handling of  
180 treated samples were performed in a biosafety cabinet. On the day of each three  
181 biologically independent tests while the UV source warmed up and measurements were  
182 taken for dose calculations, aliquots of SARS-CoV-2 (previously tittered at  $10^7$  PFU/mL)  
183 were diluted in cDMEM to make a “working stock solution” with a target titer of  $10^5$   
184 PFU/mL. For each UV dose tested, 3 mL of the working stock solution was pipetted into

185 a 3.7 cm<sup>2</sup> area and 3.5 cm diameter polystyrene tissue culture dish (VWR Catalog #  
186 82050-538) with a sterile Teflon-coated micro stir bar (VWR Catalog # 58948-353) and  
187 positioned under the UV light on a small stir plate to achieve quiescent mixing while  
188 blocking the UV light with a shutter. After removing the tissue culture dish lid, the  
189 shutter was removed to expose the sample to UV light for the calculated exposure time  
190 corresponding to the pre-determined UV dose before replacing the aperture to end the  
191 UV exposure. Immediately afterwards, the treated media was transferred to a sterile 15  
192 mL polypropylene centrifuge tube (VWR) and used for the assays described below.  
193 Working stocks for untreated samples were placed on the stir plate for a representative  
194 amount of time with the lamp off before transfer to centrifuge tube (0 mJ/cm<sup>2</sup>).

### 195 **SARS-CoV-2 plaque assay**

196 Plaque assays were used to determine PFU/mL of samples before UV treatment (0  
197 mJ/cm<sup>2</sup>) and after UV treatment (all other UV doses). The plaque assay used for this  
198 study is a modification of that which was originally developed and reported by Case et  
199 al,<sup>31</sup> and is listed here as STEPS 1-5. **(STEP 1)** At least 18 hours prior to the assay, 12-  
200 well plates were seeded with a sufficient number of Vero cells so that each well was  
201 confluent by the assay start; plates were incubated overnight at 37°C. **(STEP 2)** On the  
202 day of the assay, serial dilutions of virus-containing media (e.g UV treated virus  
203 samples) were prepared in cDMEM (1:10<sup>1</sup>, 1:10<sup>2</sup>, 1:10<sup>3</sup>, 1:10<sup>4</sup>) and warmed to 37°C.  
204 **(STEP 3)** Media from each well of the 12-well plate was gently removed via pipette and  
205 replaced with 500uL of each virus serial dilution, the volume pipetted down the side of  
206 the well so as not to disturb the Vero cell monolayer. **(STEP 4)** The plate was incubated  
207 for one hour at 37°C, 5% CO<sub>2</sub>. **(STEP 5)** During that infection incubation period, a  
208 solution comprising a 1:0.7 mixture of cDMEM and 2% methylcellulose (viscosity: 4000  
209 cP) was freshly made and warmed to 37°C in a water bath. After the one hour infection  
210 incubation period, the supernatant was removed from each well and replaced with 1 mL  
211 of the warmed cDMEM/methylcellulose mixture. **(STEP 6)** The culture plate was then  
212 returned to the incubator and left undisturbed for 3 days. On the final day,  
213 cDMEM/methylcellulose mixture was removed from each well, cells were fixed with 4%  
214 para-formaldehyde in PBS (20 minutes, room temperature), washed with PBS and

215 stained with 0.05% crystal violet (in 20% methanol). After rinsing plates with distilled  
216 water, plates were dried and plaques were counted under a light microscope at 20X  
217 magnification.

## 218 **SARS-CoV-2 outgrowth assay**

219 The virus outgrowth assay used for this study is identical to the plaque assay described  
220 above, with the exception that after **STEP 4** the virus laden media was replaced with 1  
221 mL of warm cDMEM (instead of a cDMEM/methylcellulose mixture). Afterwards, the  
222 culture plate was returned to the incubator and left undisturbed for 3 days. On the final  
223 day, the cell supernatants of each well were collected, transferred into a microcentrifuge  
224 tube, centrifuged at low speed to remove cell debris (1,000 x *g*, 10 min), aliquoted into  
225 microcentrifuge tubes, frozen and stored at -80°C. Aliquots were subsequently used for  
226 quantitative real time PCR (qRT-PCR) measurement of SARS-CoV-2 nucleocapsid (N)  
227 gene copies, as well as ELISA determination of SARS-CoV-2 N protein concentrations.

## 228 **SARS-CoV-2 N gene quantitation - N1 primer set**

229 Quantitative PCR (qPCR) was used to quantify the SARS-CoV-2 N gene directly in RNA  
230 extracts of samples before UV treatment (0 mJ/cm<sup>2</sup>) and after UV treatment (all other  
231 UV doses), and in RNA extracts of cell supernatant aliquots from outgrowth assays.  
232 RNA was extracted from samples using the QIAamp Viral RNA method (Qiagen), and  
233 converted to cDNA using the SuperScript IV first strand synthesis method with random  
234 hexamer primers (Invitrogen). cDNA was subsequently amplified with the “N1 primer  
235 set” and associated PCR conditions that were originally developed by the Centers for  
236 Disease Control<sup>35</sup>. These primers are specific to nucleotides 13-85 of the N gene (NCBI  
237 Ref Seq NC\_045512.2) and generate a short (72 nt) amplicon: 2019-nCoV\_N1-F  
238 (forward) primer, 5'-GACCCCAAATCAGCGAAAT-3'; 2019-nCoV\_N1-R (reverse)  
239 primer, 5'-TCTGGTTACTGCCAGTTGAATCTG-3'. cDNA was PCR-amplified in a  
240 quantitative PCR (q-PCR) assay comprising 1X TaqMan Universal PCR Master Mix  
241 (Applied Biosystems), the N1 forward/reverse primers described above (final  
242 concentration: 500 nM) and a fluorophore-conjugated N1 TaqMan probe (5'-FAM-

243 ACCCCGCATTACGTTTGGTGGACC-BHQ1-3'; final concentration 125 nM). q-PCR  
244 assays were run on a BioRad CFX Connect Real Time PCR system to determine  $C_T$   
245 values from samples and standards. A standard curve was generated for the N1 primer  
246 set by running serial dilutions on each plate of *in vitro* transcribed RNA converted to  
247 cDNA relating N gene copy numbers to  $C_T$  values. To generate this standard, RNA was  
248 extracted from an aliquot of our SARS-CoV-2 stock and converted to cDNA before  
249 amplification of the N gene using the N1 primer set as described above. The amplicon  
250 was visualized by agarose gel electrophoresis, gel extracted and cloned/ligated into the  
251 plasmid vector pCR II-TOPO (Invitrogen), downstream of the T7 promoter. Ligation  
252 products were transformed into *E. coli*, and mini-preps of randomly selected colonies  
253 were screened via PCR for the presence of insert. A single clone was then used to  
254 produce *in vitro* transcribed (IVT) N gene RNA—a reagent necessary for accurate gene  
255 copy number measurement—using the HiScribe T7 Quick High Yield RNA Synthesis  
256 method (New England Biolabs). After treating the IVT RNA with DNase and performing  
257 a cleanup reaction, the RNA concentration was determined via Nanodrop. The copies of  
258 single stranded N gene RNA transcripts per  $\mu\text{L}$  was determined by the following  
259 equation: [ RNA concentration (Nanodrop measurement,  $\text{ng}/\mu\text{L}$ ) x the Avogadro number  
260 ( $6.02 \times 10^{23}$ ) ] / [Predicted molecular weight of transcript (23 kDa) x  $10^9$ ]. Serial dilutions  
261 of IVT RNA were made (range:  $10^{13} \rightarrow 10^{-1}$  copies/ $\mu\text{L}$ ), converted to cDNA as above and  
262 used as standards in the N gene copy number assay described above.

### 263 **SARS-CoV-2 N gene quantitation - N1-2 primer set**

264 qPCR was used to quantify the SARS-CoV-2 N gene in RNA extracts of samples of  
265 working stocks before UV treatment ( $0 \text{ mJ}/\text{cm}^2$ ) and immediately after UV treatment (all  
266 other UV doses). RNA was extracted from samples and converted to cDNA as  
267 described above. cDNA was subsequently quantified using a combination of the CDC  
268 2019 N1 and N2 primer sets to generate a long (944 nt) amplicon: 2019-nCoV\_N1-F  
269 (forward) primer, 5'-GACCCCAAATCAGCGAAAT-3'; 2019-nCoV\_N2-R (reverse)  
270 primer, 5'-GCGCGACATTCCGAAGAA-3'. Primers were obtained from IDT and final  
271 concentrations were 500 nM, in 10  $\mu\text{L}$  SsoFast EvaGreen Supermix (BIO-RAD) and  
272 7.75  $\mu\text{L}$  nuclease free water (Fisher Scientific) and 2  $\mu\text{L}$  cDNA template. Reactions with

273 total volume of 20  $\mu$ L were run in at least technical duplicate on an Applied Biosystems  
274 QuantStudio 7 Real-Time PCR system to determine  $C_T$  values from samples and  
275 standards. For the N1-2 primer set, the standard consisted of serial dilutions of the  
276 double stranded DNA control plasmid of the complete N gene (2019-nCoV\_N\_Positive  
277 Control, IDT).

278

## 279 **SARS-CoV-2 N protein ELISA**

280 The concentration of N protein in outgrowth assay supernatants was determined using  
281 the SARS-CoV-2 Antigen Quantitative Assay Kit (ELISA) method (ADS Biotec).  
282 Manufacturer-provided calibration controls were used to establish a standard curve  
283 related N protein concentration to sample absorbance (wavelength: 450 nm). Values  
284 outside the standard curve were diluted further and rerun as appropriate. The positive  
285 signal for SARS-CoV-2 was  $2.7 \times 10^5 \pm 9.8 \times 10^4$  pg/mL in untreated virus samples at  
286 Day 0 and  $1.4 \times 10^8 \pm 3.0 \times 10^8$  pg/mL in cell culture supernatants incubated with  
287 untreated virus samples at Day 3. No N protein was detected in negative control cell  
288 culture supernatants that were incubated without virus samples.

## 289 **Graphing and Statistics**


290 Graphs were prepared using either GraphPad Prism or Microsoft Excel programs;  
291 statistical analyses (including regression using the data analysis add-in to determine  
292 standard error of regression coefficients) were performed using these programs'  
293 bundled software.  $\log_{10}$  Reduction (LR) was calculated as  $\log_{10}(N_0/N)$ , where N was  
294 viral PFU/mL in the plaque assay, N gene copies/ $\mu$ L in qPCR assays for either the short  
295 N1 amplicon or the long N1-2 amplicon, or N protein concentration in pg//mL in the  
296 ELISA assay after exposure to a given UV<sub>222</sub> dose, and  $N_0$  was the initial concentration.  
297 The level of replication in this study was three biologically independent tests, with at  
298 least technical duplicates for each assay.

## 299 **RESULTS**


### 300 **SARS-CoV-2 Infectivity Response to UV<sub>222</sub>**

301 Viral infectivity UV<sub>222</sub> dose response was characterized by exponential decay kinetics  
302 (Figure 2). At a mean initial viral titer of  $6.51 \times 10^4$  PFU/mL, the pseudo first order rate  
303 constant for viral disinfection was  $-1.48 \text{ cm}^2/\text{mJ}$  ( $R^2 = 0.89$ ). When expressed as LR of  
304 viral infectivity after exposure to a given UV dose, the linear rate constant was  $0.64$   
305  $\text{cm}^2/\text{mJ}$  ( $R^2 = 0.95$ ), which equates to a  $D_{90}$  (dose for 1  $\log_{10}$  or 90% inactivation) =  $1.6$   
306  $\text{mJ}/\text{cm}^2$ . Doses ranges and initial Vero cell confluence were only sufficient in the Test 3  
307 experimental replicate to quantify a dose response. However, in Test 2, the mean initial  
308 viral titer of  $3.54 \times 10^4$  PFU/mL in untreated samples was reduced to below detection by  
309 the first dose tested of  $10 \text{ mJ}/\text{cm}^2$ , equivalent to a LR of at least 4.25 logs. These  
310 results were also consistent with qualitative results from Test 1, where Vero cells  
311 appeared mostly dead in the untreated samples, appeared increasingly healthy through  
312 doses  $0.7$  and  $1.4 \text{ mJ}/\text{cm}^2$ , and appeared healthy at doses above  $2 \text{ mJ}/\text{cm}^2$ .  
313

314



315



316

317 **Figure 2:** (A) SARS-CoV-2 titers measured by plaque assay 3 days after sample  
318 exposure to each UV<sub>222</sub> dose (dark circles) were fit with an exponential model starting at  
319 the mean initial (0 mJ/cm<sup>2</sup>) viral titer of 6.51x10<sup>4</sup> PFU/mL through responses up to and  
320 including 8 mJ/cm<sup>2</sup> where PFU/mL first dropped below the assay detection limit (DL) of  
321 2 PFU/mL (hollow circles). Error bars represent standard deviation of at least two  
322 technical replicates. (B) SARS-CoV-2 log<sub>10</sub> reductions (LR) of viral titers after exposure  
323 to each UV<sub>222</sub> dose (dark circles) were fit with a linear model forced through the origin at  
324 0 mJ/cm<sup>2</sup> through responses up to and including 8 mJ/cm<sup>2</sup> where LR first exceeded the  
325 DL of 4.51 logs (hollow circles).

## 326 SARS-CoV-2 N Gene and Protein Response to UV<sub>222</sub>

327 For the short amplicon spanning the N1 region of the N gene (CDC 2019), viral RNA  
328 damage in response to UV<sub>222</sub> immediately after treatment was also characterized by

329 exponential decay kinetics (Figure 3A). When expressed as LR of N1 copies/ $\mu$ L in  
330 qPCR reactions after exposure to a given UV dose, the linear rate constant was  $0.069 \pm$   
331  $0.005 \text{ cm}^2/\text{mJ}$  (slope  $\pm$  standard error,  $R^2 = 0.92$ ). The N1 dose response was modeled  
332 using the linear region between 0 - 20  $\text{mJ}/\text{cm}^2$  to avoid tailing in the dose response.  
333 When including only doses up to  $10\text{mJ}/\text{cm}^2$  as for the plaque assay, the slope and  $R^2$  of  
334 the N1 gene damage dose response was the same as for doses up to  $20 \text{ mJ}/\text{cm}^2$ .  
335 Compared with the LR rate constant for of SARS-CoV-2 infectivity measured by plaque  
336 assay, the LR rate constant of N gene damage measured by N1 qPCR was  
337 approximately 10-fold lower. Across all tests, the positive signal for SARS-CoV-2 in the  
338 N1 assay was  $10.75 \pm 0.25 \log_{10}$  copies/ $\mu$ L in cell cultures infected with untreated virus  
339 ( $0 \text{ mJ}/\text{cm}^2$ ),  $4.89 \pm 0.86 \log_{10}$  copies/ $\mu$ L in uninfected cell culture supernatants,  $5.49$   
340  $\log_{10}$  copies/ $\mu$ L in RNA extraction negative control,  $3.36 \pm 0.24 \log_{10}$  copies/ $\mu$ L in no  
341 template RT-qPCR reaction controls (concentration data and standard curves shown in  
342 Supplementary Figures S2 and S3). Despite this background signal, dose responses  
343 were still discernable. For the N1 dose response after 3 days in the outgrowth assay for  
344 doses up to 0 - 20  $\text{mJ}/\text{cm}^2$ , the linear rate constant was  $0.260 \pm 0.036 \text{ cm}^2/\text{mJ}$  (slope  $\pm$   
345 standard error,  $R^2 = 0.76$ ). Although a positive dose response was apparent and the  
346 slope was closer to the plaque assay (indicating better ability to predict plaque assay  
347 dose response with combined cell culture with qPCR), the increased variability  
348 introduced by cell culture decreased the strength of the regression.  
349  
350 For the long amplicon spanning both the N1 and N2 regions of N gene (CDC 2019),  
351 viral RNA damage in response to  $\text{UV}_{222}$  immediately after treatment was also  
352 characterized by exponential decay (Figure 3B). The linear rate constant for LR versus  
353  $\text{UV}_{222}$  dose was  $0.054 \pm 0.003 \text{ cm}^2/\text{mJ}$  (slope  $\pm$  standard error,  $R^2 = 0.94$ ). Compared  
354 with the LR rate constant for of SARS-CoV-2 infectivity measured by plaque assay, the  
355 LR rate constant of N gene damage measured by N1-2 qPCR was approximately 10-  
356 fold lower. This similarity indicates that increasing the amplicon length did not increase  
357 the ability to detect gene damage that correlates with loss of viral infectivity. Across all  
358 tests, the positive signal for SARS-CoV-2 in the N1-2 assay was  $4.6 \pm 0.1 \log_{10}$   
359 copies/ $\mu$ L in cell cultures infected with untreated virus, undetected in uninfected cell

360 culture supernatants, and  $0.8 \pm 1.4$  copies/ $\mu$ L in no template RT-qPCR reaction controls  
361 (concentration data and standard curves shown in Supplementary Figures S2 and S3).  
362 Because the long amplicon assay was used to investigate potential for improved  
363 measurement of disinfection dose response without culture, no Day 3 samples were  
364 analyzed.

365

366 Although no dose response was observed for LR of the N protein versus UV<sub>222</sub> dose  
367 immediately after treatment for doses up to 40 mJ/cm<sup>2</sup> ( $0.002 \pm 0.001$  cm<sup>2</sup>/mJ, slope  $\pm$   
368 standard error,  $R^2 = 0.21$ ), a stronger dose response was observed in Day 3 cell culture  
369 supernatants for doses up to 20 mJ/cm<sup>2</sup> ( $0.243 \pm 0.028$  cm<sup>2</sup>/mJ, slope  $\pm$  standard error,  
370  $R^2 = 0.21$ ) (Figure 3C). Across all tests, the positive signal for SARS-CoV-2 in the N  
371 protein assay was  $2.69 \times 10^5 \pm 9.83 \times 10^4$  pg/mL in untreated virus samples on Day 0,  
372  $1.41 \times 10^8 \pm 2.99 \times 10^8$  in Day 3 cell culture supernatants infected with untreated virus,  
373 and below detection in uninfected cell culture supernatants (concentration data and  
374 standard curves shown in Supplementary Figures S2 and S3). Gene copies/ $\mu$ L for both  
375 qPCR assays and protein pg/mL for the ELISA assay are shown for each UV<sub>222</sub> dose in  
376 Supplementary Figure S2 and standard curves for all assays are shown in  
377 Supplementary Figure S3.

378

379


380

381

382

383

384 **Figure 3:** (A) SARS-CoV-2 N gene damage immediately after UV treatment (Day 0) and  
385 after incubation of samples with host cells (Day 3) expressed as  $\log_{10}$  reduction of N1  
386 (short amplicon) copies/ $\mu\text{L}$  in qPCR reactions. (B) SARS-CoV-2 N gene damage  
387 immediately after UV treatment (Day 0) expressed as  $\log_{10}$  reduction of N1-2 (long  
388 amplicon) copies/ $\mu\text{L}$  in qPCR reactions. (C) SARS-CoV-2 N protein concentration  
389 measured by ELISA expressed as  $\log_{10}$  reduction of N protein concentration (pg/mL) in  
390 samples immediately after UV treatment (Day 0) and after incubation of samples with  
391 host cells (Day 3). SARS-CoV-2  $\log_{10}$  reductions of the N1 amplicon, N1-2 amplicon, or



392 N protein versus UV<sub>222</sub> dose were fit with a linear model forced through the origin at 0  
393 mJ/cm<sup>2</sup> through responses up to and including 20 mJ/cm<sup>2</sup> indicated by filled circles.  
394 Points not included in models are indicated by hollow circles.

395

## 396 **DISCUSSION**

397 This study provides the first rigorous UV<sub>222</sub> dose response kinetics for SARS-CoV-2 in  
398 aqueous solution, but there are limitations that must be acknowledged. Most  
399 importantly, this study was conducted using virions suspended in aqueous solution.  
400 This is only a starting point for quantifying dose response kinetics for airborne virus  
401 disinfection that is most relevant for this virus, where many factors such as temperature,  
402 humidity, air flow dynamics, and UV reactor specifics will impact dose responses.  
403 Previous studies comparing disinfection kinetics of infectious agents in air at increasing  
404 relative humidity to those in water<sup>36–41</sup> indicate that these water dose responses may  
405 present a conservative estimate of airborne disinfection kinetics because humidity in  
406 many indoor environments is conditioned to reduce infectious agent persistence

407

408 One additional limitation of this study related to UV<sub>222</sub> application in indoor environments  
409 is that the disinfection impact of any ozone production by vacuum UV wavelengths  
410 potentially emitted by the KrCl excilamp was not measured, but can likely be neglected  
411 due to high airflows in the biosafety cabinet and BSL3 facility. The negative air quality  
412 impacts and building material degradation by ozone potentially generated by these  
413 lamps, and the potential health hazards and building material solarization from  
414 wavelengths below 240 nm and the nonzero emission at wavelengths above 240 nm  
415 (Supplementary Figure S1), should also be considered when weighing the benefits of  
416 reducing infectious disease transmission by UV<sub>222</sub> for COVID-19 and other infectious  
417 diseases.

418

419 Considering these limitations, these data provide a strong foundation for future  
420 development and application of UV<sub>222</sub> for reducing airborne viral transmission. UV<sub>222</sub> is  
421 both 4.2 times safer for human exposure (the threshold limit values for human UV

422 exposure are 25 mJ/cm<sup>2</sup> and 6 mJ/cm<sup>2</sup> at 222 and 254 nm, respectively<sup>41</sup>) and at least  
423 1.3 times as effective at disinfecting SARS-CoV-2 (the D<sub>90</sub> we observed for UV<sub>222</sub> (1.6  
424 mJ/cm<sup>2</sup>) is lower than recently predicted by genomic modeling for UV<sub>254</sub> (2.15  
425 mJ/cm<sup>2</sup>)<sup>42</sup>). A recent study applying continuous UV<sub>222</sub> at doses below these threshold  
426 limit values to treat other airborne coronaviruses demonstrated multiple logs of  
427 inactivation within minutes<sup>43</sup>. This low wavelength advantage for SARS-CoV-2  
428 disinfection is consistent with a study where UV<sub>222</sub> was more than twice as effective as  
429 UV<sub>254</sub> against MS2 bacteriophage<sup>34</sup> and with other viral action spectra indicating greater  
430 sensitivity at 222 nm than 254 nm<sup>26</sup>. A recent review<sup>44</sup> predicted the median D<sub>90</sub> for  
431 coronavirus disinfection by UV<sub>254</sub> to be 3.7 mJ/cm<sup>2</sup>. Our results and these predictions  
432 are in general agreement with recent UV<sub>222</sub> and UV<sub>254</sub> disinfection studies of SARS-  
433 CoV-2 as recently reviewed<sup>41</sup>. However, some of these studies are still in the process  
434 of peer review and/or did not use standardized UV disinfection procedures that allow  
435 comparisons between experiments and precise quantification of doses. In the only  
436 UV<sub>222</sub> SARS-CoV-2 surface decontamination study to date <sup>45</sup>, researchers report 0.94  
437 LR after 10 second exposure to 0.1 mW/cm<sup>2</sup>. Although UV dose cannot be calculated  
438 for this study in the absence of sample absorbance and differences in experimental  
439 setup, these results demonstrate a high degree of susceptibility of SARS-CoV-2 to  
440 UV<sub>222</sub> and generally align with ours.

441  
442 Considering our data in context of literature, UV<sub>222</sub> is a promising disinfection method for  
443 SARS-CoV-2 in aqueous solution. These infectivity and molecular dose response data  
444 could immediately inform measures to prevent transmission by water or wastewater  
445 where infectious SARS-CoV-2 and other viruses have been shown to be potentially  
446 persistent for days<sup>46,47</sup>. Although tailing was observed in dose responses for molecular  
447 assays and may have been contributed from clumping of virus in the protein-laden  
448 growth media, viruses were disinfected below detection in plaque assays, indicating that  
449 aggregation did not interfere with complete viral inactivation. We did not observe a  
450 strong relationship between the kinetics of N gene damage (measured by qPCR with a  
451 short and long amplicon) and disinfection, which could reflect that protein damage  
452 contributes more to disinfection than genome damage for SARS-CoV-2. One study of

453 MS2 bacteriophage found RNA genome damage to be closely related to and thus  
454 contributed to disinfection kinetics<sup>27</sup>, whereas a study of Adenovirus found DNA genome  
455 damage not to be closely related to disinfection<sup>48</sup>. This disparity between these viruses  
456 with different structures and hosts was further demonstrated when it was shown that  
457 protein damage, especially to external capsid proteins, contributes more strongly to UV  
458 disinfection of Adenovirus<sup>49</sup>. However, we also did not see a strong association  
459 between the kinetics of N protein damage and disinfection. Because we only measured  
460 the N protein that closely associates with the viral genome, we may have missed  
461 damage to external proteins such as the spike protein which are on the surface to  
462 absorb incoming UV radiation and are vital in infection of host cells<sup>50</sup>. Additionally, the  
463 confirmation and sequence of the genome and proteins can affect UV genetic  
464 damage<sup>51-55</sup>, so the N protein and gene may not be the targets that primarily contribute  
465 to disinfection-inducing molecular damage. These factors could explain the weak  
466 relationships we observed between disinfection kinetics and N gene damage or N  
467 protein damage, and warrant further investigation to unravel the mechanisms of  
468 disinfection at this and other UV wavelengths. While these mechanistic complexities  
469 remain to be resolved, the disinfection kinetics we report indicate the high degree of  
470 susceptibility of SARS-CoV-2 in aqueous solution to UV<sub>222</sub>.

471

## 472 **ACKNOWLEDGEMENTS**

473 This work was supported by funds from The Ohio State University (OSU) Sustainability  
474 Institute; OSU Infectious Disease Institute; OSU Department of Civil, Environmental,  
475 and Geodetic Engineering (Chair: Dr. Allison MacKay); OSU Department of Microbial  
476 Infection & Immunity (Chair: Dr. Eugene Oltz); and National Institutes of Health (U54  
477 CA260582). Anna Herman of AquiSense Technologies shared a list of references to  
478 SARS-CoV-2 UV disinfection studies. The UV<sub>222</sub> light source (USHIO Care222®) was  
479 provided by USHIO, Inc. through material transfer agreement 2020-2654 to Hull at  
480 OSU.

481

## 482 REFERENCES

- 483 (1) Samet, J. M.; Prather, K.; Benjamin, G.; Lakdawala, S.; Lowe, J.-M.; Reingold, A.;  
484 Volckens, J.; Marr, L. Airborne Transmission of SARS-CoV-2: What We Know.  
485 *Clin. Infect. Dis.* **2021**. <https://doi.org/10.1093/cid/ciab039>.
- 486 (2) Tang, J. W.; Bahnfleth, W. P.; Bluysen, P. M.; Buonanno, G.; Jimenez, J. L.;  
487 Kurnitski, J.; Li, Y.; Miller, S.; Sekhar, C.; Morawska, L.; et al. Dismantling Myths  
488 on the Airborne Transmission of Severe Acute Respiratory Syndrome  
489 Coronavirus (SARS-CoV-2). *J. Hosp. Infect.* **2021**.  
490 <https://doi.org/10.1016/j.jhin.2020.12.022>.
- 491 (3) Hess, C. B.; Buchwald, Z. S.; Stokes, W.; Nasti, T. H.; Switchenko, J. M.;  
492 Weinberg, B. D.; Steinberg, J. P.; Godette, K. D.; Murphy, D.; Ahmed, R.; et al.  
493 Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia: Planned Day 7  
494 Interim Analysis of a Registered Clinical Trial. *Cancer* **2020**, *126* (23), 5109–5113.  
495 <https://doi.org/10.1002/cncr.33130>.
- 496 (4) Wang, Y.; Zhang, D.; Du, G.; Du, R.; Zhao, J.; Jin, Y.; Fu, S.; Gao, L.; Cheng, Z.;  
497 Lu, Q.; et al. Remdesivir in Adults with Severe COVID-19: A Randomised,  
498 Double-Blind, Placebo-Controlled, Multicentre Trial. *Lancet* **2020**, *395* (10236),  
499 1569–1578. [https://doi.org/10.1016/S0140-6736\(20\)31022-9](https://doi.org/10.1016/S0140-6736(20)31022-9).
- 500 (5) Ison, M. G.; Scheetz, M. H. Understanding the Pharmacokinetics of Favipiravir:  
501 Implications for Treatment of Influenza and COVID-19. *EBioMedicine*. Elsevier  
502 B.V. January 1, 2021. <https://doi.org/10.1016/j.ebiom.2020.103204>.
- 503 (6) Cavalcanti, A. B.; Zampieri, F. G.; Rosa, R. G.; Azevedo, L. C. P.; Veiga, V. C.;  
504 Avezum, A.; Damiani, L. P.; Marcadenti, A.; Kawano-Dourado, L.; Lisboa, T.; et  
505 al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.  
506 *N. Engl. J. Med.* **2020**, *383* (21), 2041–2052.  
507 <https://doi.org/10.1056/nejmoa2019014>.
- 508 (7) Monk, P. D.; Marsden, R. J.; Tear, V. J.; Brookes, J.; Batten, T. N.; Mankowski,  
509 M.; Gabbay, F. J.; Davies, D. E.; Holgate, S. T.; Ho, L. P.; et al. Safety and  
510 Efficacy of Inhaled Nebulised Interferon Beta-1a (SNG001) for Treatment of  
511 SARS-CoV-2 Infection: A Randomised, Double-Blind, Placebo-Controlled, Phase

- 512 2 Trial. *Lancet Respir. Med.* **2020**. [https://doi.org/10.1016/S2213-2600\(20\)30511-](https://doi.org/10.1016/S2213-2600(20)30511-)  
513 7.
- 514 (8) Simonovich, V. A.; Burgos Pratx, L. D.; Scibona, P.; Beruto, M. V.; Vallone, M. G.;  
515 Vázquez, C.; Savoy, N.; Giunta, D. H.; Pérez, L. G.; Sánchez, M. del L.; et al. A  
516 Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. *N.*  
517 *Engl. J. Med.* **2020**. <https://doi.org/10.1056/nejmoa2031304>.
- 518 (9) Joyner, M. J.; Carter, R. E.; Senefeld, J. W.; Klassen, S. A.; Mills, J. R.; Johnson,  
519 P. W.; Theel, E. S.; Wiggins, C. C.; Bruno, K. A.; Klompas, A. M.; et al.  
520 Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. *N.*  
521 *Engl. J. Med.* **2021**. <https://doi.org/10.1056/nejmoa2031893>.
- 522 (10) Weinreich, D. M.; Sivapalasingam, S.; Norton, T.; Ali, S.; Gao, H.; Bhore, R.;  
523 Musser, B. J.; Soo, Y.; Rofail, D.; Im, J.; et al. REGN-COV2, a Neutralizing  
524 Antibody Cocktail, in Outpatients with Covid-19. *N. Engl. J. Med.* **2020**, *384* (3).  
525 <https://doi.org/10.1056/nejmoa2035002>.
- 526 (11) Chen, P.; Nirula, A.; Heller, B.; Gottlieb, R. L.; Boscia, J.; Morris, J.; Huhn, G.;  
527 Cardona, J.; Mocherla, B.; Stosor, V.; et al. SARS-CoV-2 Neutralizing Antibody  
528 LY-CoV555 in Outpatients with Covid-19. *N. Engl. J. Med.* **2020**, *384* (3).  
529 <https://doi.org/10.1056/nejmoa2029849>.
- 530 (12) Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. *N.*  
531 *Engl. J. Med.* **2020**. <https://doi.org/10.1056/nejmoa2021436>.
- 532 (13) Stone, J. H.; Frigault, M. J.; Serling-Boyd, N. J.; Fernandes, A. D.; Harvey, L.;  
533 Foulkes, A. S.; Horick, N. K.; Healy, B. C.; Shah, R.; Bensaci, A. M.; et al. Efficacy  
534 of Tocilizumab in Patients Hospitalized with Covid-19. *N. Engl. J. Med.* **2020**, *383*  
535 (24), 2333–2344. <https://doi.org/10.1056/nejmoa2028836>.
- 536 (14) Cao, Y.; Wei, J.; Zou, L.; Jiang, T.; Wang, G.; Chen, L.; Huang, L.; Meng, F.;  
537 Huang, L.; Wang, N.; et al. Ruxolitinib in Treatment of Severe Coronavirus  
538 Disease 2019 (COVID-19): A Multicenter, Single-Blind, Randomized Controlled  
539 Trial. *J. Allergy Clin. Immunol.* **2020**, *146* (1), 137-146.e3.  
540 <https://doi.org/10.1016/j.jaci.2020.05.019>.
- 541 (15) Polack, F. P.; Thomas, S. J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.;  
542 Perez, J. L.; Pérez Marc, G.; Moreira, E. D.; Zerbini, C.; et al. Safety and Efficacy

- 543 of the BNT162b2 mRNA Covid-19 Vaccine. *N. Engl. J. Med.* **2020**, 383 (27),  
544 2603–2615. <https://doi.org/10.1056/nejmoa2034577>.
- 545 (16) Goel, S.; Hawi, S.; Goel, G.; Thakur, V. K.; Agrawal, A.; Hoskins, C.; Pearce, O.;  
546 Hussain, T.; Upadhyaya, H. M.; Cross, G.; et al. Resilient and Agile Engineering  
547 Solutions to Address Societal Challenges Such as Coronavirus Pandemic. *Mater.*  
548 *Today Chem.* **2020**, 17. <https://doi.org/10.1016/j.mtchem.2020.100300>.
- 549 (17) Gerchman, Y.; Mamane, H.; Friedman, N.; Mandelboim, M. UV-LED Disinfection  
550 of Coronavirus: Wavelength Effect. *J. Photochem. Photobiol. B Biol.* **2020**, 212.  
551 <https://doi.org/10.1016/j.jphotobiol.2020.112044>.
- 552 (18) Kariwa, H.; Fujii, N.; Takashima, I. Inactivation of SARS Coronavirus by Means of  
553 Povidone-Iodine, Physical Conditions and Chemical Reagents. *Dermatology*  
554 **2006**, 212 (SUPPL. 1), 119–123. <https://doi.org/10.1159/000089211>.
- 555 (19) Darnell, M. E. R.; Subbarao, K.; Feinstone, S. M.; Taylor, D. R. Inactivation of the  
556 Coronavirus That Induces Severe Acute Respiratory Syndrome, SARS-CoV. *J.*  
557 *Viol. Methods* **2004**, 121 (1), 85–91.  
558 <https://doi.org/10.1016/j.jviromet.2004.06.006>.
- 559 (20) Rabenau, H. F.; Cinatl, J.; Morgenstern, B.; Bauer, G.; Preiser, W.; Doerr, H. W.  
560 Stability and Inactivation of SARS Coronavirus. *Med. Microbiol. Immunol.* **2005**,  
561 194 (1–2), 1–6. <https://doi.org/10.1007/s00430-004-0219-0>.
- 562 (21) Pfeifer, G. P.; Besaratinia, A. UV Wavelength-Dependent DNA Damage and  
563 Human Non-Melanoma and Melanoma Skin Cancer. *Photochemical and*  
564 *Photobiological Sciences*. Royal Society of Chemistry 2012, pp 90–97.  
565 <https://doi.org/10.1039/c1pp05144j>.
- 566 (22) Jose, J. G.; Pitts, D. G. Wavelength Dependency of Cataracts in Albino Mice  
567 Following Chronic Exposure. *Exp. Eye Res.* **1985**, 41 (4), 545–563.  
568 [https://doi.org/10.1016/S0014-4835\(85\)80011-7](https://doi.org/10.1016/S0014-4835(85)80011-7).
- 569 (23) Bjørklund, G.; Dadar, M.; Mutter, J.; Aaseth, J. The Toxicology of Mercury:  
570 Current Research and Emerging Trends. *Environmental Research*. Academic  
571 Press Inc. 2017, pp 545–554. <https://doi.org/10.1016/j.envres.2017.08.051>.
- 572 (24) Buonanno, M.; Ponnaiya, B.; Welch, D.; Stanislauskas, M.; Randers-Pehrson, G.;  
573 Smilenov, L.; Lowy, F. D.; Owens, D. M.; Brenner, D. J. Germicidal Efficacy and

- 574 Mammalian Skin Safety of 222-Nm UV Light. *Radiat. Res.* **2017**, *187* (4), 483–  
575 491. <https://doi.org/10.1667/RR0010CC.1>.
- 576 (25) Kaidzu, S.; Sugihara, K.; Sasaki, M.; Nishiaki, A.; Igarashi, T.; Tanito, M.  
577 Evaluation of Acute Corneal Damage Induced by 222-Nm and 254-Nm Ultraviolet  
578 Light in Sprague–Dawley Rats. *Free Radic. Res.* **2019**, *53* (6), 611–617.  
579 <https://doi.org/10.1080/10715762.2019.1603378>.
- 580 (26) Beck, S. E.; Wright, H. B.; Hargy, T. M.; Larason, T. C.; Linden, K. G. Action  
581 Spectra for Validation of Pathogen Disinfection in Medium-Pressure Ultraviolet  
582 (UV) Systems. *Water Res.* **2015**, *70*, 27–37.  
583 <https://doi.org/10.1016/j.watres.2014.11.028>.
- 584 (27) Beck, S. E.; Rodriguez, R. A.; Hawkins, M. A.; Hargy, T. M.; Larason, T. C.;  
585 Linden, K. G. Comparison of UV-Induced Inactivation and RNA Damage in MS2  
586 Phage across the Germicidal UV Spectrum. *Appl. Environ. Microbiol.* **2016**, *82*  
587 (5), 1468–1474. <https://doi.org/10.1128/AEM.02773-15>.
- 588 (28) Beck, S. E.; Hull, N. M.; Poepping, C.; Linden, K. G. Wavelength-Dependent  
589 Damage to Adenoviral Proteins Across the Germicidal UV Spectrum. *Environ. Sci.*  
590 *Technol.* **2018**. <https://doi.org/10.1021/acs.est.7b04602>.
- 591 (29) Eischeid, A. C.; Linden, K. G. Molecular Indications of Protein Damage in  
592 Adenoviruses after UV Disinfection. *Appl. Environ. Microbiol.* **2011**, *77* (3), 1145–  
593 1147. <https://doi.org/10.1128/AEM.00403-10>.
- 594 (30) Hull, N. M.; Linden, K. G. Synergy of MS2 Disinfection by Sequential Exposure to  
595 Tailored UV Wavelengths. *Water Res.* **2018**.  
596 <https://doi.org/10.1016/j.watres.2018.06.017>.
- 597 (31) Case, J. B.; Bailey, A. L.; Kim, A. S.; Chen, R. E.; Diamond, M. S. Growth,  
598 Detection, Quantification, and Inactivation of SARS-CoV-2. *Virology* **2020**, *548*,  
599 39–48. <https://doi.org/10.1016/j.virol.2020.05.015>.
- 600 (32) Bolton, J. R.; Linden, K. G. Standardization of Methods for Fluence (UV Dose)  
601 Determination in Bench-Scale UV Experiments. *J. Environ. Eng.* **2003**, *129* (3),  
602 209–215. [https://doi.org/10.1061/\(asce\)0733-9372\(2003\)129:3\(209\)](https://doi.org/10.1061/(asce)0733-9372(2003)129:3(209)).
- 603 (33) Linden, K. G.; Darby, J. L. Estimating Effective Germicidal Dose from Medium  
604 Pressure UV Lamps. *J. Environ. Eng.* **1997**, *123* (11), 1142–1149.

- 605 [https://doi.org/10.1061/\(asce\)0733-9372\(1997\)123:11\(1142\)](https://doi.org/10.1061/(asce)0733-9372(1997)123:11(1142)).
- 606 (34) Hull, N. M.; Linden, K. G. Synergy of MS2 Disinfection by Sequential Exposure to  
607 Tailored UV Wavelengths. *Water Res.* **2018**.  
608 <https://doi.org/10.1016/j.watres.2018.06.017>.
- 609 (35) CDC. Real-time RT-PCR Primers and Probes for COVID-19 | CDC  
610 <https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html>  
611 (accessed Feb 4, 2021).
- 612 (36) Peccia, J.; Hernandez, M. UV-Induced Inactivation Rates for Airborne  
613 *Mycobacterium Bovis* BCG. *J. Occup. Environ. Hyg.* **2004**, *1* (7), 430–435.  
614 <https://doi.org/10.1080/15459620490458495>.
- 615 (37) Walker, C. M.; Ko, G. Effect of Ultraviolet Germicidal Irradiation on Viral Aerosols.  
616 *Environ. Sci. Technol.* **2007**, *41* (15), 5460–5465.  
617 <https://doi.org/10.1021/es070056u>.
- 618 (38) Jordan, P.; Werth, H. M.; Shelly, M.; Mark, H. Effects of Relative Humidity on the  
619 Ultraviolet Induced Inactivation of Airborne Bacteria. *Aerosol Sci. Technol.* **2001**,  
620 *35* (3), 728–740. <https://doi.org/10.1080/02786820152546770>.
- 621 (39) Kowalski, W. *Ultraviolet Germicidal Irradiation Handbook: UVGI for Air and*  
622 *Surface Disinfection*; Springer Berlin Heidelberg, 2009.  
623 <https://doi.org/10.1007/978-3-642-01999-9>.
- 624 (40) Tseng, C.-C.; Li, C.-S. Inactivation of Virus-Containing Aerosols by Ultraviolet  
625 Germicidal Irradiation. *Aerosol Sci. Technol.* **2005**, *39* (12), 1136–1142.  
626 <https://doi.org/10.1080/02786820500428575>.
- 627 (41) Raeiszadeh, M.; Adeli, B. A Critical Review on Ultraviolet Disinfection Systems  
628 against COVID-19 Outbreak: Applicability, Validation, and Safety Considerations.  
629 **2020**. <https://doi.org/10.1021/acsp Photonics.0c01245>.
- 630 (42) Pendyala, B.; Patras, A.; Pokharel, B.; D’Souza, D. Genomic Modeling as an  
631 Approach to Identify Surrogates for Use in Experimental Validation of SARS-CoV-  
632 2 and HuNoV Inactivation by UV-C Treatment. *Front. Microbiol.* **2020**, *11*, 2406.  
633 <https://doi.org/10.3389/fmicb.2020.572331>.
- 634 (43) Buonanno, M.; Welch, D.; Shuryak, I.; Brenner, D. J. Far-UVC Light (222 Nm)  
635 Efficiently and Safely Inactivates Airborne Human Coronaviruses. *Sci. Rep.* **2020**,

- 636 10 (1). <https://doi.org/10.1038/s41598-020-67211-2>.
- 637 (44) Heßling, M.; Hönes, K.; Vatter, P.; Lingenfelder, C. Ultraviolet Irradiation Doses  
638 for Coronavirus Inactivation - Review and Analysis of Coronavirus  
639 Photoinactivation Studies. *GMS Hyg. Infect. Control* **2020**, *15*, Doc08.  
640 <https://doi.org/10.3205/dgkh000343>.
- 641 (45) Kitagawa, H.; Nomura, T.; Nazmul, T.; Omori, K.; Shigemoto, N.; Sakaguchi, T.;  
642 Ohge, H. Effectiveness of 222-Nm Ultraviolet Light on Disinfecting SARS-CoV-2  
643 Surface Contamination. *Am. J. Infect. Control* **2020**, *0* (0).  
644 <https://doi.org/10.1016/j.ajic.2020.08.022>.
- 645 (46) Bivins, A.; Greaves, J.; Fischer, R.; Yinda, K. C.; Ahmed, W.; Kitajima, M.;  
646 Munster, V. J.; Bibby, K. Persistence of SARS-CoV-2 in Water and Wastewater.  
647 *Environ. Sci. Technol. Lett.* **2020**, *7* (12), 937–942.  
648 <https://doi.org/10.1021/acs.estlett.0c00730>.
- 649 (47) Ye, Y.; Ellenberg, R. M.; Graham, K. E.; Wigginton, K. R. Survivability,  
650 Partitioning, and Recovery of Enveloped Viruses in Untreated Municipal  
651 Wastewater. *Environ. Sci. Technol.* **2016**, *50* (10), 5077–5085.  
652 <https://doi.org/10.1021/acs.est.6b00876>.
- 653 (48) Rodríguez, R. A.; Bounty, S.; Linden, K. G. Long-Range Quantitative PCR for  
654 Determining Inactivation of Adenovirus 2 by Ultraviolet Light. *J. Appl. Microbiol.*  
655 **2013**, *114* (6), 1854–1865. <https://doi.org/10.1111/jam.12169>.
- 656 (49) Beck, S. E.; Hull, N. M.; Poepping, C.; Linden, K. G. Wavelength-Dependent  
657 Damage to Adenoviral Proteins Across the Germicidal UV Spectrum. *Environ. Sci.*  
658 *Technol.* **2018**, *52* (1), 223–229. <https://doi.org/10.1021/acs.est.7b04602>.
- 659 (50) Shang, J.; Wan, Y.; Luo, C.; Ye, G.; Geng, Q.; Auerbach, A.; Li, F. Cell Entry  
660 Mechanisms of SARS-CoV-2. *Proc. Natl. Acad. Sci. U. S. A.* **2020**, *117* (21).  
661 <https://doi.org/10.1073/pnas.2003138117>.
- 662 (51) Rockey, N.; Young, S.; Kohn, T.; Pecson, B.; Wobus, C. E.; Raskin, L.; Wigginton,  
663 K. R. UV Disinfection of Human Norovirus: Evaluating Infectivity Using a Genome-  
664 Wide PCR-Based Approach. *Environ. Sci. Technol.* **2020**, *54* (5), 2851–2858.  
665 <https://doi.org/10.1021/acs.est.9b05747>.
- 666 (52) Ye, Y.; Chang, P. H.; Hartert, J.; Wigginton, K. R. Reactivity of Enveloped Virus

- 667 Genome, Proteins, and Lipids with Free Chlorine and UV254. *Environ. Sci.*  
668 *Technol.* **2018**, 52 (14), 7698–7708. <https://doi.org/10.1021/acs.est.8b00824>.
- 669 (53) Wigginton, K. R.; Menin, L.; Sigstam, T.; Gannon, G.; Cascella, M.; Hisham, J;  
670 Hamidane, B.; Tsybin, Y. O.; Waridel, P.; Kohn, T. UV Radiation Induces  
671 Genome-Mediated, Site-Specific Cleavage in Viral Proteins. *ChemBioChem* **2012**,  
672 13, 837–845. <https://doi.org/10.1002/cbic.201100601>.
- 673 (54) Wigginton, K. R.; Kohn, T. Virus Disinfection Mechanisms: The Role of Virus  
674 Composition, Structure, and Function. *Current Opinion in Virology*. Elsevier B.V.  
675 February 1, 2012, pp 84–89. <https://doi.org/10.1016/j.coviro.2011.11.003>.
- 676 (55) Wigginton, K. R.; Pecson, B. M.; Sigstam, T.; Bosshard, F.; Kohn, T. Virus  
677 Inactivation Mechanisms: Impact of Disinfectants on Virus Function and Structural  
678 Integrity. *Environ. Sci. Technol.* **2012**, 46 (21), 12069–12078.  
679 <https://doi.org/10.1021/es3029473>.
- 680
- 681

682 **SARS-CoV-2 disinfection in aqueous solution**  
683 **by UV<sub>222</sub> from a krypton chlorine excilamp**  
684  
685

686 **AUTHORS**


687 Richard T. Robinson<sup>1,2</sup>, Najmus Mahfooz<sup>1</sup>, Oscar Rosas-Mejia<sup>1</sup>, Yijing Liu<sup>3</sup>, Natalie M.  
688 Hull<sup>3,4\*</sup>  
689

690 **AFFILIATIONS**

- 691 5. Department of Microbial Infection and Immunity, The Ohio State University,  
692 Columbus, OH, USA  
693 6. Infectious Diseases Institute, The Ohio State University, Columbus, OH, USA  
694 7. Department of Civil, Environmental, and Geodetic Engineering, The Ohio State  
695 University, Columbus, OH, USA  
696 8. Sustainability Institute, The Ohio State University, Columbus, OH, USA  
697 \* Corresponding author: Natalie Hull, hull.305@osu.edu, 2070 Neil Ave, Hitchcock  
698 417C, Columbus, OH,43210  
699  
700

701 **CONTENTS**

702 This supplementary information contains Figure S1 describing lamp emission and  
703 sample absorbance, Table S1 describing key parameters for UV exposures and dose  
704 calculations, Figure S2 standard curves for qPCR and ELISA assays, and Figure S3  
705 molecular assay concentration data for N gene or N protein at each UV dose.  
706  
707



708

709

710 **Figure S1:** (A) The raw spectral emission from 200 - 300 nm of the filtered excilamp  
711 (USHIO Care222<sup>®</sup>) was interpolated and relativized to the peak emission at 222 nm for  
712 use in UV dose calculations and plotted on log scale to show orders of magnitude less  
713 but non-zero emission at filtered wavelengths > 240 nm. (B) The absorbance spectrum  
714 from 200 - 300 nm of SARS-CoV-2 at  $\sim 10^5$  PFU/mL in cDMEM was measured for each  
715 of three Tests for use in UV dose calculations.

716


717

718 **Table S1:** Summary of key UV dose calculation parameters for each independent Test.


	<b>Test 1</b>	<b>Test 2</b>	<b>Test 3</b>
<b>Date</b>	1-Sep-20	16-Sep-20	4-Nov-20
<b>UV doses (mJ/cm<sup>2</sup>)</b>	0, 0.7, 1.1, 1.4, 1.7, 2.0, 2.7	0, 10, 16, 20, 25, 30, 40	0, 2, 4, 8, 12, 16, 20, 30
<b>Sample exposure times (sec)</b>	0, 29, 45, 57, 72, 87, 115	0, 214, 343, 429, 536, 643, 856	0, 84, 168, 336, 504, 672, 840, 1260
<b>Incident irradiance at center of petri dish (mW/cm<sup>2</sup>)</b>	1.100	2.490	1.200
<b>Divergence factor</b>	0.9444	0.9091	0.9091
<b>Petri factor</b>	0.9459	0.9147	0.9791
<b>Water factor</b>	0.0247	0.0232	0.0230
<b>Average irradiance through sample depth (mW/cm<sup>2</sup>)</b>	0.0236	0.0466	0.0238

719


720



721



722




723

724 **Figure S2:** N gene RT-qPCR standard curves gene copies/ $\mu$ L reaction for the (A) short


725 N1 amplicon and (B) long N1-2 amplicon and (C) ELISA N protein standard curve.

726 Colors differentiate individual assay runs.


727



728



729



730

731 **Figure S3:** N gene RT-qPCR copies/μL reaction for the (A) short N1 amplicon and (B)  
732 long N1-2 amplicon, where error bars represent standard deviation of at least two  
733 technical replicates and could include technical replicates averaged across dilutions.  
734 (C) N protein ELISA pg/mL, where error bars represent standard deviation of at least  
735 two technical replicates and could include technical replicates averaged across  
736 dilutions. Day 0 samples were analyzed immediately after UV irradiation, where Day 3  
737 samples were analyzed in culture supernatants after incubation of samples with host  
738 cells.